Ram Eitan

Ram Eitan

Auto-generated profile, based on publicly available information

Ram Eitan

Faculty of Medicine, Tel-Aviv University, Tel Aviv, Israel

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
AMAssaf Menachem
Assaf Menachem
ZAZoya Alteber
Zoya Alteber
GCGady Cojocaru
Gady Cojocaru
TKTal Fridman Kfir
Tal Fridman Kfir
DBDan Blat
Dan Blat
EOEran Ophir
Eran Ophir
Recombinant cytokines have limited anticancer efficacy mostly due to a narrow therapeutic window and systemic adverse effects. IL18 is an inflammasome-induced proinflammatory cytokine, which enhances T- and NK-cell activity and stimulates IFNγ production. The activity of IL18 is naturally blocked by a high-affinity endogenous binding protein (IL18BP). IL18BP is induced in the tumor microenvironment (TME) in response to IFNγ upregulation in a negative feedback mechanism. In this study, we found that IL18 is upregulated in the TME compared with the periphery across multiple human tumors and most of it is bound to IL18BP. Bound IL18 levels were largely above the amount required for T-cell activation in vitro, implying that releasing IL18 in the TME could lead to potent T-cell activation. To restore the activity of endogenous IL18, we generated COM503, a high-affinity anti-IL18BP that blocks the IL18BP:IL18 interaction and displaces precomplexed IL18, thereby enhancing T- and NK-cell activation. In vivo, administration of a surrogate anti-IL18BP, either alone or in combination with anti-PD-L1, resulted in significant tumor growth inhibition and increased survival across multiple mouse tumor models. Moreover, the anti-IL18BP induced pronounced TME-localized immune modulation including an increase in polyfunctional nonexhausted T- and NK-cell numbers and activation. In contrast, no increase in inflammatory cytokines and lymphocyte numbers or activation state was observed in serum and spleen. Taken together, blocking IL18BP using an Ab is a promising approach to harness cytokine biology for the treatment of cancer.

14 February 2012 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
HKHaim Krissi
Haim Krissi
RERam Eitan
Ram Eitan
RERam Edward
Ram Edward
YPYoav Peled
Yoav Peled

13 December 2012 in Acta Haematologica
Verified
Journal Article
Closed access
PDF file
ASAdi Shacham-Abulafia
Adi Shacham-Abulafia
RNRan Nagar
Ran Nagar
RERam Eitan
Ram Eitan
HLHanoch Levavi
Hanoch Levavi
GSGad Sabah
Gad Sabah
PRPia-Sophia Raanani
Pia-Sophia Raanani
Primary Burkitt’s lymphoma of the ovary is extremely rare. We report the case of a 39-year-old woman who presented with a 1-month history complaints of night sweats, abdominal pain and dyspnea. Physical examination demonstrated pleural effusions, ascites and an abdominal mass. Imaging showed enlargement of both ovaries extending to the surrounding tissue. Frozen sections on explorative laparotomy suggested granulosa cell tumor of the ovary, and thus extensive debulking was carried out. The final pathological report was compatible with Burkitt’s lymphoma. A systematic literature review revealed another 16 cases of ovarian Burkitt’s lymphoma. Characteristics predictive for the diagnosis of Burkitt’s lymphoma were: younger age, bilateral ovarian involvement, a rapidly progressive course and high LDH levels.

16 May 2024 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
ZAZoya Alteber
Zoya Alteber
GCGady Cojocaru
Gady Cojocaru
RGRoy Z. Granit
Roy Z. Granit
IBInbal Barbiro
Inbal Barbiro
AWAssaf Wool
Assaf Wool
EOEran Ophir
Eran Ophir
Cancers that are poorly immune infiltrated pose a substantial challenge, with current immunotherapies yielding limited clinical success. Stem-like memory T cells (TSCM) have been identified as a subgroup of T cells that possess strong proliferative capacity and that can expand and differentiate following interactions with dendritic cells (DCs). In this study, we explored the pattern of expression of a recently discovered inhibitory receptor poliovirus receptor-related immunoglobulin domain protein (PVRIG) and its ligand, poliovirus receptor-related ligand 2 (PVRL2), in the human tumor microenvironment. Using spatial and single-cell RNA transcriptomics data across diverse cancer indications, we found that among the T-cell checkpoints, PVRIG is uniquely expressed on TSCM and PVRL2 is expressed on DCs in immune aggregate niches in tumors. PVRIG blockade could therefore enhance TSCM–DC interactions and efficiently drive T-cell infiltration to tumors. Consistent with these data, following PVRIG blockade in patients with poorly infiltrated tumors, we observed immune modulation including increased tumor T-cell infiltration, T-cell receptor (TCR) clonality, and intratumoral T-cell expansion, all of which were associated with clinical benefit. These data suggest PVRIG blockade as a promising strategy to induce potent antitumor T-cell responses, providing a novel approach to overcome resistance to immunotherapy in immune-excluded tumors.

1 December 2005 in Nature Clinical Practice Oncology
Verified
Journal Article
Closed access
RERam Eitan
Ram Eitan
DCDennis S Chi
Dennis S Chi

28 September 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
GGGilli Galore-Haskel
Gilli Galore-Haskel
EMEfrat Merhavi-Shoham
Efrat Merhavi-Shoham
MSMika Shapiro
Mika Shapiro
RBRoni Bareli
Roni Bareli
NDNaama Dror
Naama Dror
GMGal Markel
Gal Markel
Immune checkpoint inhibitors have improved cancer outcomes; however, many patients fail to respond, highlighting the need for novel targets. Herpes virus entry mediator (HVEM) is an immuoregulator with both inhibitory and stimulatory functions, making it a promising therapeutic candidate. We have developed anti-4CB1, a fully human monoclonal antibody (mAb) that selectively blocks HVEM interactions with BTLA and CD160. Its activity was evaluated in vitro using human tumor-infiltrating lymphocytes, peripheral blood mononuclear cells, and M1 macrophages, as well as in ex vivo patient-derived tumor samples and in vivo transgenic and humanized mouse models. HVEM expression was also assessed in serum and tumor tissues. Anti-4CB1 enhanced T-cell activation and cytotoxicity, evidenced by increased tumor cell killing, upregulation of activation markers (41BB and CD107a), and elevated IFNγ and TNFα secretion. It also promoted macrophage-mediated phagocytosis. In ex vivo analyses of 49 patient-derived tumor samples, anti-4CB1 increased cytotoxicity in 28.5% of cases, including samples unresponsive to anti-PD1. In vivo, anti-4CB1 demonstrated significant antitumor activity as monotherapy and showed enhanced efficacy in combination with anti-PD1. Additionally, higher tumor HVEM expression correlated with improved response to checkpoint blockade, whereas elevated soluble HVEM levels were associated with reduced responsiveness to anti-HVEM. Anti-4CB1 enhances both adaptive and innate antitumor immunity and shows activity in anti-PD1–resistant settings. These findings support its potential as a novel therapeutic agent and suggest HVEM as a predictive biomarker for immunotherapy response.